Biochem Biophys Res Commun

1. MAO J, Wang C, Li T, Shao Q, et al
   Systematic pharmacology-guided analysis of the therapeutic mechanism of Sedum sarmentosum against chronic liver injury.
   Biochem Biophys Res Commun. 2026;810:153514.
   

   >> Share

   
   
2. TAKAHATA Y, Yamauchi T, Tsuruta A, Koyanagi S, et al
   The circadian gene CHRONO drives hepatocellular carcinoma proliferation via G1/S cell cycle transition.
   Biochem Biophys Res Commun. 2026;813:153610.
   

   >> Share

   
   
3. HUI H, Guzailiayi A, Sirui H, Danping L, et al
   Sleep deprivation exacerbates hepatic steatosis by promoting hepatic inflammation and oxidative stress through gut microbiota dysbiosis in metabolic dysfunction-associated fatty liver disease rat.
   Biochem Biophys Res Commun. 2026;813:153588.
   

   >> Share

   
   

   
   BMC Cancer

4. LI Y, Wang Y, Tang H, Luo X, et al
   TACE combined with tislelizumab and lenvatinib in the treatment of intermediate-to-advanced hepatocellular carcinoma: a retrospective real-world study.
   BMC Cancer. 2026 Mar 21. doi: 10.1186/s12885-026-15879.
   

   >> Share

   
   

   
   BMC Gastroenterol

5. JIAO Y, Guo L, Lu Y, Li M, et al
   Multi-omics analysis and experimental validation uncovers prognosis significance of IKBIP in patients with hepatocellular carcinoma: a multicenter cohort study.
   BMC Gastroenterol. 2026 Mar 19. doi: 10.1186/s12876-026-04756.
   

   >> Share

   
   
6. ZHANG Y, Yin K, Pan Y, Ren G, et al
   Long-term outcomes and bleeding risk factors in pancreatic portal hypertension: a retrospective cohort study.
   BMC Gastroenterol. 2026 Mar 18. doi: 10.1186/s12876-026-04700.
   

   >> Share

   
   
7. FOUAD Y, Mostafa AM, Abdelhalim SM, Hassanine AA, et al
   Dietary recommendations for patients with chronic liver diseases: the need for increased awareness among non-hepatologist physicians.
   BMC Gastroenterol. 2026 Mar 13. doi: 10.1186/s12876-026-04685.
   

   >> Share

   
   

   
   Cancer Res

8. BARROWS KM, Porat-Shliom N
   Hot Zones for Liver Cancer: Metabolic Zonation, Ferroptosis, and the Origins of HCC.
   Cancer Res. 2026;86:1347-1350.
   

   >> Share

   
   
9. SUN Y, Luo C, Yang H, Ye J, et al
   Lactylation Converts ABHD6 into a Mitochondrial Regulator that Drives Lenvatinib Resistance in Hepatocellular Carcinoma.
   Cancer Res. 2026 Mar 20. doi: 10.1158/0008-5472.CAN-25-4282.
   

   >> Share

   
   

   
   Eur Radiol

10. LING W, Ye F, Wu Q, Liu M, et al
    Prospective evaluation of the semi-quantitative hepatic subcapsular flow score and hepatic capsular retraction sign in the diagnosis of biliary atresia.
    Eur Radiol. 2026 Mar 15. doi: 10.1007/s00330-026-12392.
    

    >> Share

    
    

    
    Gut

11. HUANG HY, Wu K, Qu LM, Sun XD, et al
    Token-guided multimodal prognosis in hepatocellular carcinoma: a framework steered by tumour-stroma ratio.
    Gut. 2026 Mar 18:gutjnl-2025-337945. doi: 10.1136/gutjnl-2025-337945.
    

    >> Share

    
    
12. GEHL V, O'Rourke CJ, Cornillet M, Nousias O, et al
    Molecular and cellular consequences of tumour-autonomous IL-6 signalling in intrahepatic cholangiocarcinoma.
    Gut. 2026 Mar 19:gutjnl-2025-337579. doi: 10.1136/gutjnl-2025-337579.
    

    >> Share

    
    
13. GUO Y, Zhang G, Fu X, Jiang S, et al
    Hypoxia-related and immune phenotype-related fusion model for non-invasive prognostication of hepatocellular carcinoma treated by TACE: a multicentre study.
    Gut. 2026 Mar 19:gutjnl-2025-337938. doi: 10.1136/gutjnl-2025-337938.
    

    >> Share

    
    

    
    Hepatology

14. PARTHASARATHY G, Malhi H, Bajaj JS
    Therapeutic manipulation of the microbiome in liver disease.
    Hepatology. 2026;83:948-969.
    

    >> Share

    
    
15. ZHANG Y, Cao C, Li C, Witt RG, et al
    Physical exercise in liver diseases.
    Hepatology. 2026;83:915-930.
    

    >> Share

    
    
16. YANG A, Yan X, Wang Y, Han Q, et al
    ECM1 produced by hepatic stellate cells serves as gate keeper of liver homeostasis in hepatic fibrosis.
    Hepatology. 2026 Mar 19. doi: 10.1097/HEP.0000000000001715.
    

    >> Share

    
    
17. SIDHU G
    When "trace" is not trivial: Mild ascites as the missing prognostic middle ground in cirrhosis.
    Hepatology. 2026;83:695-696.
    

    >> Share

    
    
18. CAO P, Niu M, Zhu H, Zhang C, et al
    Hepatic STEAP4 promotes liver regeneration by regulating lysosomal iron homeostasis and membrane integrity in acetaminophen-induced liver injury.
    Hepatology. 2026 Mar 16. doi: 10.1097/HEP.0000000000001718.
    

    >> Share

    
    
19. LOOMBA R, Daniel PCN, Amangurbanova M, Bettencourt R, et al
    Head-to-head comparison of MASH resolution index versus FAST for noninvasive prediction of resolution of MASH on biopsy.
    Hepatology. 2026;83:907-914.
    

    >> Share

    
    
20. NOMDEN M, Kuipers F, Lexmond WS, Gu T, et al
    Pretreatment serum bile acid composition and predictability of subsequent response to odevixibat in patients with bile salt export pump (BSEP) deficiency.
    Hepatology. 2025 Jul 11. doi: 10.1097/HEP.0000000000001430.
    

    >> Share

    
    
21. MARTINS A, Khakoo NS, Reddy A, Reynolds JM, et al
    Comparative effectiveness of peroxisome proliferator-activated receptor agonists as second-line therapies for primary biliary cholangitis: A systematic review and network meta-analysis.
    Hepatology. 2025 Jul 15. doi: 10.1097/HEP.0000000000001465.
    

    >> Share

    
    
22. SLOVIC N, Mishra S, Paul S, Oudot MA, et al
    Chemoprevention of hepatocellular carcinoma by next-generation antipsychotic aripiprazole.
    Hepatology. 2026 Mar 13. doi: 10.1097/HEP.0000000000001719.
    

    >> Share

    
    

    
    Int J Cancer

23. ALI E, Ye W, Pavlov S, Cervenkova L, et al
    Distribution and prognostic value of T-cells in primary colorectal cancer and adjacent non-tumor mucosa in stage IV versus stage I-III patients.
    Int J Cancer. 2025 Dec 30. doi: 10.1002/ijc.70319.
    

    >> Share

    
    
24. CAI Z, Qiu L, Li L, Li Z, et al
    Sequential personalized neoantigen vaccination following first-line treatments demonstrates safety and efficacy in advanced hepatocellular carcinoma.
    Int J Cancer. 2026 Mar 16. doi: 10.1002/ijc.70445.
    

    >> Share

    
    

    
    J Comput Assist Tomogr

25. WANG S, Meng T, Peng L, Zeng Q, et al
    Ultra-Low-Dose Liver CT With Artificial Intelligence Iterative Reconstruction.
    J Comput Assist Tomogr. 2026;50:180-186.
    

    >> Share

    
    

    
    J Gastroenterol Hepatol

26. MIN EK, Kim SS, Ahn B, Kim DG, et al
    Diagnostic Value of MR Elastography and MRI-Proton Density Fat Fraction in Cirrhosis Based on Explant Liver Histology.
    J Gastroenterol Hepatol. 2026 Mar 13. doi: 10.1111/jgh.70316.
    

    >> Share

    
    
27. AKKUS E, Yasar HA
    Immune Checkpoint Inhibitor-Based Adjuvant Treatment Versus Surveillance in Curatively Treated Hepatocellular Carcinoma: a Systematic Review and Meta-Analysis.
    J Gastroenterol Hepatol. 2026 Mar 13. doi: 10.1111/jgh.70318.
    

    >> Share

    
    

    
    J Hepatol

28. SU YY, Hsu C
    Response to "Conversion surgery as a missing outcome in first-line immunotherapy trials for hepatocellular carcinoma".
    J Hepatol. 2026 Mar 17:S0168-8278(26)00139-X. doi: 10.1016/j.jhep.2026.
    

    >> Share

    
    
29. ZENG T, Huang Y, He H, Chang J, et al
    IFRD1 orchestrates hepatocyte metabolism and macrophage interactions to facilitate liver regeneration.
    J Hepatol. 2026 Mar 18:S0168-8278(26)00137-6. doi: 10.1016/j.jhep.2026.
    

    >> Share

    
    
30. LUUKKONEN PK
    Targeting metabolism to modify cirrhosis: Lessons from FGF21 therapy in MASH.
    J Hepatol. 2026 Mar 19:S0168-8278(26)00131-5. doi: 10.1016/j.jhep.2026.
    

    >> Share

    
    
31. TROPPMAIR MR, Ricci A, Scarlini S, Pelucchi S, et al
    Characterization of ferroportin disease and SLC40A1-related hemochromatosis - Results from the EASL non-HFE registry.
    J Hepatol. 2026;84:728-737.
    

    >> Share

    
    
32. YANG B, Bu T, Wang Q
    Hepatic CTSB is Kupffer cell-enriched, whereas disease-state stratification is more strongly captured by endotoxin/TLR4 programmes.
    J Hepatol. 2026 Mar 16:S0168-8278(26)00135-2. doi: 10.1016/j.jhep.2026.
    

    >> Share

    
    
33. BATISTA MN, Bordignon J, Pamplona Mosimann AL, Bobrowski T, et al
    An immunocompetent murine model of virus-elicited liver fibrosis and hepatocellular carcinoma.
    J Hepatol. 2026 Mar 11:S0168-8278(26)00085-1. doi: 10.1016/j.jhep.2026.
    

    >> Share

    
    
34. LACKNER C, Gouw ASH, Avancini Ferreira Alves V, Arola J, et al
    Consensus position statements for the standardized application of histological grading and staging systems in MASH clinical trials.
    J Hepatol. 2026;84:693-701.
    

    >> Share

    
    
35. LI R, Liu J, Ye F, He S, et al
    Microbial metabolism dysfunction induced by transarterial chemoembolization aggravates postprocedural liver injury in HCC.
    J Hepatol. 2026;84:808-822.
    

    >> Share

    
    
36. KAMDAR Z, Neumann E, Howe K, Long D Jr, et al
    DNAJ-PKAc induces metabolic rewiring and enhanced glutamine flux in fibrolamellar HCC.
    J Hepatol. 2026;84:793-807.
    

    >> Share

    
    

    
    Minerva Gastroenterol (Torino)

37. EL-SHABRAWI MH, Suoh M, Almuhaidib S, Alqahtani SA, et al
    Metabolic liver disease research in the Arab world: a bibliometric analysis of trends, collaborations, and disparities (2006-2024).
    Minerva Gastroenterol (Torino). 2026;72:37-50.
    

    >> Share

    
    

    
    PLoS One

38. TANG Z, Deng Y, He Y, Chen Y, et al
    Trend of liver cancer attributable to alcohol use in China from 1992 to 2021: An age-period-cohort analysis study.
    PLoS One. 2026;21:e0343137.
    

    >> Share

    
    
39. ZHANG J, Feng L
    Analysis of 6-week mortality and influencing factors in patients with liver cirrhosis and portal vein thrombosis complicated by acute gastrointestinal bleeding.
    PLoS One. 2026;21:e0345079.
    

    >> Share

    
    
40. NIRIELLA MA, Wijesingha IP, Prabagar K, Abeynayake D, et al
    Evaluating the quality of social media content on metabolic dysfunction associated steatotic liver disease: An experience from a lower middle-income country.
    PLoS One. 2026;21:e0343573.
    

    >> Share

    
    
41. SPRINKLES JK, Qin Q, Steward C, Howard AG, et al
    Plasma lipidomics, choline metabolites, and metabolic-associated steatotic liver disease (MASLD): A Coronary Artery Risk Development in Young Adults (CARDIA) study.
    PLoS One. 2026;21:e0341462.
    

    >> Share

    
    
42. WANG X, Xie C, Deng Y, Ren X, et al
    The association between psoriasis and nonalcoholic fatty liver disease: Mediation analysis involving inflammatory biomarkers among U.S. adults.
    PLoS One. 2026;21:e0344681.
    

    >> Share

    
    
43. LIN J, Huang M, Shen L
    The association between dietary inflammatory index and non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    PLoS One. 2026;21:e0345297.
    

    >> Share

    
    

    
    Radiol Cardiothorac Imaging

44. DESAI TJ, Barhate GN, Tavri OJ, Kerkar PG, et al
    Hepatic Capsular Weblike Collaterals in Coarctation of the Aorta.
    Radiol Cardiothorac Imaging. 2026;8:e250546.
    

    >> Share

    
    

    
    Radiol Imaging Cancer

45. LIU K, Zheng B, Zhang Y, Wang B, et al
    Clinical Utility of Deep Learning-based Multiple Arterial Phase MRI in Hepatocellular Carcinoma.
    Radiol Imaging Cancer. 2026;8:e250538.
    

    >> Share

    
    

    
    Radiology

46. KUHNEL C, Schmidt TN, Freesmeyer M, Schricke M, et al
    Transarterial Radioembolization: Medical Staff Dosimetry for (90)Y-Resin, (90)Y-Glass, and (166)Ho-PLLA Microspheres.
    Radiology. 2026;318:e251822.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share